Abstract
One of the critical points in the pathogenesis of aortic aneurysms (AAs) is the disruption of the balance between vascular extracellular matrix (ECM) deposition and degradation. AAs are common features in some genetically determined diseases of the connective tissue, such as Marfan and Ehlers-Danlos. Acquired factors determining an enhanced inflammatory state of the arterial wall also play a key role. Previous studies have determined the role of tumor growth factor β (TGF-β); as a principal mediator of the pathogenesis of the alterations of the arterial wall homeostasis in AAs. The medical management of any AA is mainly focused on the use of pharmacological agents that reduce hemodynamic stress of the aortic wall, since hypertension is the major risk factor for the enlargement and rupture of the AAs. However, this is far from being a comprehensive pathophysiology-based therapeutic approach. Drugs potentially able to reduce the release of TGF-β may play a role in the pathogenesis of the AAs. They work by improving matrix repair, decreasing the proteolytic pattern and inhibition of angiotensin-converting enzyme (ACE) as well as preventing angiotensin II-induced angiotensin type-1 receptor (AT1R) activation. A new pathophysiology-based therapeutic approach, involving the mechanisms leading to the rupture of the AAs, could represent an additional tool in combination with the current established antihypertensive therapy.
Keywords: Pathophysiology, medical therapy, aortic aneurysms, atherosclerosis, insulin resistance, metalloproteinases, tumor growth factor ß, angiotensin-converting enzyme, hypertension, inflammation
Current Vascular Pharmacology
Title: Medical Therapy of Aortic Aneurysms: A Pathophysiology-Based Approach
Volume: 9 Issue: 5
Author(s): Giovanna Muscogiuri, Gian Pio Sorice, Devjit Tripathy, Alberto O. Chavez, Alberto Davalli, Richard A. Lange and Franco Folli
Affiliation:
Keywords: Pathophysiology, medical therapy, aortic aneurysms, atherosclerosis, insulin resistance, metalloproteinases, tumor growth factor ß, angiotensin-converting enzyme, hypertension, inflammation
Abstract: One of the critical points in the pathogenesis of aortic aneurysms (AAs) is the disruption of the balance between vascular extracellular matrix (ECM) deposition and degradation. AAs are common features in some genetically determined diseases of the connective tissue, such as Marfan and Ehlers-Danlos. Acquired factors determining an enhanced inflammatory state of the arterial wall also play a key role. Previous studies have determined the role of tumor growth factor β (TGF-β); as a principal mediator of the pathogenesis of the alterations of the arterial wall homeostasis in AAs. The medical management of any AA is mainly focused on the use of pharmacological agents that reduce hemodynamic stress of the aortic wall, since hypertension is the major risk factor for the enlargement and rupture of the AAs. However, this is far from being a comprehensive pathophysiology-based therapeutic approach. Drugs potentially able to reduce the release of TGF-β may play a role in the pathogenesis of the AAs. They work by improving matrix repair, decreasing the proteolytic pattern and inhibition of angiotensin-converting enzyme (ACE) as well as preventing angiotensin II-induced angiotensin type-1 receptor (AT1R) activation. A new pathophysiology-based therapeutic approach, involving the mechanisms leading to the rupture of the AAs, could represent an additional tool in combination with the current established antihypertensive therapy.
Export Options
About this article
Cite this article as:
Muscogiuri Giovanna, Pio Sorice Gian, Tripathy Devjit, O. Chavez Alberto, Davalli Alberto, A. Lange Richard and Folli Franco, Medical Therapy of Aortic Aneurysms: A Pathophysiology-Based Approach, Current Vascular Pharmacology 2011; 9 (5) . https://dx.doi.org/10.2174/157016111796642724
DOI https://dx.doi.org/10.2174/157016111796642724 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional Neuroimaging in Memory and Memory Disturbances
Current Medical Imaging Recent Patents on Electrospun Biomedical Nanostructures: An Overview
Recent Patents on Biomedical Engineering (Discontinued) Increased OPG Expression and Impaired OPG/TRAIL Ratio in the Aorta of Diabetic Rats
Medicinal Chemistry Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology Feasibility and Efficacy of Low-profile Visual Intraluminal Support Device: A Single Center Five-year Experience
Current Neurovascular Research High Dose Immunoglobulin (IVIG) May Reduce the Incidence of Langerhans Cell Histiocytosis (LCH)-Associated Central Nervous System Involvement
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Combination Therapy of Vascular Diseases and Fangjiomics: When West Meets East in the Era of Phenomics)
Current Vascular Pharmacology The Heart and Brain Imaging in Lone Atrial Fibrillation – Are We Surprised?
Current Pharmaceutical Design Anti-Platelet Treatment of Middle-Sized Abdominal Aortic Aneurysms
Current Vascular Pharmacology Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy
Current Pharmaceutical Design Ultrasonographic Assessment of Cirrhosis and Portal Hypertension
Current Medical Imaging Adrenergic and V1-ergic Agonists/Antagonists Affecting Recovery from Brain Trauma in the Lund Project Act on Astrocytes
Current Signal Transduction Therapy Noncardiac Surgery: Evaluating and Minimizing Cardiac Risk
Current Cardiology Reviews FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI Subjects
Current Radiopharmaceuticals Platelet Toll-Like Receptor Expression: The Link Between “Danger” Ligands and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) 9.4T Magnetic Resonance Imaging of the Mouse Circle of Willis Enables Serial Characterization of Flow-Induced Vascular Remodeling by Computational Fluid Dynamics
Current Neurovascular Research The Extracellular Matrix of Blood Vessels
Current Pharmaceutical Design Therapeutic Hypothermia as a Neuroprotective Strategy in Neonatal Hypoxic-Ischemic Brain Injury and Traumatic Brain Injury
Current Molecular Medicine Systemic Inflammatory Response, Bacterial Translocation and Nitric Oxide Donors
Inflammation & Allergy - Drug Targets (Discontinued) The Predictive Value of Lipid Markers in Vascular Disease
Current Pharmaceutical Design